BioCentury This Week Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus
23 snips
Sep 23, 2025 Pfizer is making waves with a $4.9 billion acquisition that revives its obesity drug ambitions. The discussion includes insights from a high-profile meeting in the U.K. focusing on drug pricing and NHS challenges. Experts also dive into the intricacies of U.S. drug pricing policies and the potential impact of China’s regulations. Additionally, the latest advancements in narcolepsy treatments spark excitement, especially after successes in phase III trials. Tune in for a whirlwind tour of the life sciences landscape!
AI Snips
Chapters
Transcript
Episode notes
Capital And CDMO Limits Favor Big Pharma
- Small independent obesity biotechs face steep capital and CDMO constraints to compete against Lilly and Novo at commercial scale.
- Many startups opt to be acquired to access manufacturing, trial capacity and commercialization muscle.
Cambridge Meeting Buzz Despite Setbacks
- Simone reported high energy and optimism at BioCentury Grand Rounds in Cambridge despite recent big pharma pullbacks.
- Attendees focused on science and translational bottlenecks rather than walking around with long faces.
UK Investment Hits Turn On Drug Pricing
- Major pharma pullbacks in the UK centered on concerns about NHS drug pricing and returns on investment.
- Patrick Vallance acknowledged the pricing problem and said government discussions are happening at senior levels to try to bring industry back to the table.